Edgewise Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 100.16 million compared to USD 67.64 million a year ago. Basic loss per share from continuing operations was USD 1.57 compared to USD 1.26 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.05 USD | +5.44% | +8.95% | +55.85% |
Apr. 23 | Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU | MT |
Apr. 22 | RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.85% | 1.51B | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023